These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid generic competition, wrote Connor Hart for the Wall ...

The treatment led to rapid, robust reduction of fluid in the retina in patients with macular edema following retinal vein occlusion, Bayer said. The high-dose drug has the potential to become a ...

The JV will focus on discovering and developing new drugs for conditions including haemophilia, heart disease in infants and a form of blindness called Stargardt. Bayer is just the latest in a ...

Finance, Bayer’s market cap has fallen more than 44 ... streamlining structures in the pharma division accelerated the launch of Nubeqa - a drug that’s already generated over $1 billion USD.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Additionally, the ophthalmology drug Eylea™ saw an 8.6% increase in sales. However, these positive developments were offset by a 23% decline in sales of Xarelto, which is Bayer's blockbuster ...

Bayer acquires rights to Cytokinetics' heart drug in Japan Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug development ...